As of the end of fiscal year 2024, Tracenable has captured detailed data on Jiangsu Hengrui Pharmaceuticals's corporate ownership structure, offering an in-depth view of its significant subsidiaries and their importance within the group.a
The dataset includes information on 46 subsidiaries, identified as material based on their financial importance, operational scale, or strategic contribution to Jiangsu Hengrui Pharmaceuticals's consolidated operations.a
Tracenable's data also records the effective ownership percentages that Jiangsu Hengrui Pharmaceuticals holds across these entities, providing transparency into its corporate control, ownership hierarchy, and group governance practices.a
| Entity Name | Country | Type | Ownership | LEI | PermID |
|---|---|---|---|---|---|
REISTONE BIOPHARMA
(CAYMAN) LTDa | CYM | Subsidiary | 81.63% | 0000000 | 0000000 |
RETROLEAD (CAYMAN)
BIOPHARMA CO., LTDa | CYM | Subsidiary | 60% | 0000000 | 0000000 |
HENGRUI SG PTE. LTD.a | SGP | Subsidiary | 100% | 0000000 | 0000000 |
RETROLEAD (BVI)
BIOPHARMA CO.,LTDa | VGB | Subsidiary | 60% | 0000000 | 0000000 |
江苏科信医药销售有限公司a | CHN | Subsidiary | 100% | 0000000 | 0000000 |
江苏原创药物研发有限公司a | CHN | Subsidiary | 67.65% | 0000000 | 0000000 |
江苏原创药物研发有限公司a | CHN | Subsidiary | 5.88% | 0000000 | 0000000 |
江苏盛迪亚实业有限公司a | CHN | Subsidiary | 100% | 0000000 | 0000000 |
上海恒瑞医药有限公司a | CHN | Subsidiary | 100% | 0000000 | 0000000 |
上海盛迪医药有限公司a | CHN | Subsidiary | 100% | 0000000 | 0000000 |
上海森辉医药有限公司a | CHN | Subsidiary | 100% | 0000000 | 0000000 |
瑞利迪（上海）生物医药有限 公司a | CHN | Subsidiary | 60% | 0000000 | 0000000 |
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| Showing 12 out of 46 entities. Get complete coverage in the full dataset. | |||||
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Jiangsu Hengrui Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Tracenable's group entities dataset provides geographic insights into Jiangsu Hengrui Pharmaceuticals's significant subsidiaries, revealing their location around the world.a
In total, the Jiangsu Hengrui Pharmaceuticals group includes 46 significant subsidiaries distributed across 13 countries, illustrating the company's governance network, operational footprint, and geographical consolidation structure.a
This visualization highlights the geographical distribution of Jiangsu Hengrui Pharmaceuticals's corporate structure, helping assess its international exposure, operational reach, and cross-border governance landscape.a
In 2024, Tracenable identified that the Jiangsu Hengrui Pharmaceuticals group consisted of45 significant subsidiaries, located across 13 countries.a
This represents a focused geographic presence, reflecting the company's core operational centers or key strategic markets rather than a full view of its global entity network.a
Jiangsu Hengrui Pharmaceuticals's significant subsidiaries are primarily located in Asia and North America, which together host 84.78% of its material entities.a
This concentration suggests that the company's strategic and operational priorities are centered in these key markets, consistent with its focus on financially material or high-impact operations.
Jiangsu Hengrui Pharmaceuticals exhibits a limited level of transparency concerning its corporate ownership structure.
The disclosure covers only a small number of significant subsidiaries, typically those with material financial or operational relevance.a
Without full group hierarchy or equity details, it offers a restricted view of Jiangsu Hengrui Pharmaceuticals's broader ownership network, making it harder to assess the company's consolidated structure or cross-entity control.
Yes. Tracenable's data shows that 4 entities (8.7%) are registered in jurisdictions commonly classified as low-tax or offshore financial centers, such as Cayman Islands or British Virgin Islands.a
This may indicate tax optimization strategies or the use of special-purpose vehicles (SPVs) within Jiangsu Hengrui Pharmaceuticals's ownership structure.